| Literature DB >> 32948686 |
Mélanie Chesneau1,2, Hoa Le Mai1,2, Richard Danger1,2, Sabine Le Bot1,2, Thi-Van-Ha Nguyen1,2, Josselin Bernard1,2, Cyrielle Poullaouec1,2, Pierrick Guerrif1,3, Sophie Conchon1,2, Magali Giral1,2,3, Béatrice Charreau1,2, Nicolas Degauque1,2, Sophie Brouard4,2,3.
Abstract
Granzyme B-expressing B cells have been shown to be an important regulatory B cell subset in humans. However, it is unclear which subpopulations of B cells express GZMB under normal conditions and which protocols effectively induce ex vivo expansion of GZMB+ B cells. We found that in the peripheral blood of normal individuals, plasmablasts were the major B cell subpopulation that expressed GZMB. However, when using an in vitro plasmablast differentiation protocol, we obtained only 2% GZMB+ B cells. Nevertheless, using an expansion mixture containing IL-21, anti-BCR, CpG oligodeoxynucleotide, CD40L, and IL-2, we were able to obtain more than 90% GZMB+ B cells after 3 d culture. GZMB+ B cells obtained through this protocol suppressed the proliferation of autologous and allogenic CD4+CD25- effector T cells. The suppressive effect of GZMB+ B cells was partially GZMB dependent and totally contact dependent but was not associated with an increase in effector T cell apoptosis or uptake of GZMB by effector T cells. Interestingly, we showed that GZMB produced by B cells promoted GZMB+ B cell proliferation in ERK1/2-dependent manner, facilitating GZMB+ B cell expansion. However, GZMB+ B cells tended to undergo apoptosis after prolonged stimulation, which may be considered a negative feedback mechanism to limit their uncontrolled expansion. Finally, we found that expanded GZMB+ B cells exhibited a regulatory phenotype and were enriched in CD307bhi, CD258hiCD72hi, and CD21loPD-1hi B cell subpopulations. Our study, to our knowledge, provides new insight into biology of GZMB+ B cells and an efficient method to expand GZMB+ B cells for future cell therapy applications.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32948686 DOI: 10.4049/jimmunol.2000335
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422